NSF award 2451302 · Yolo Immune INC
SBIR Phase I: Novel Immuno-therapy for Specific Depletion of IgG4 Subtype of Autoantibodies
Final report due
28 January 2027
in 102 days · The award ends on 30 September 2026.
GrantClerk is a private service. We are not NSF or any government agency.
Dates this award owes
NSF emails you about this too.
- Final report due28 Jan 2027in 102 days
award ending 2026-09-30 · Research.gov
- Project outcomes report due28 Jan 2027in 102 days
award ending 2026-09-30 · Research.gov
- Award is closed out28 Jan 2027in 102 days
award ending 2026-09-30 · Research.gov
Annual report dates come from the budget period on your award notice. That date is not public, so it is not shown here.
How we got this date
- NSF lists this award's end date as 30 September 2026.
- NSF rules say the final report is due no later than 120 days after that.
- So the final report is due by 28 January 2027.
Get a note before each report date
Add this award to your desk. We email you before each date and keep the dates in one place.
Renews each year until you cancel. Cancel any time from your account.
Award card
- Award number
- 2451302
- Period of support
- 1 Oct 2025 – 30 Sep 2026
- Amount
- $304,665
- Awardee
- Yolo Immune INC, SAN Carlos, CA
- Program
- SBIR Phase I
- Directorate
- TIP
Abstract
The broader/commercial impact of this Small Business Innovation Research (SBIR) Phase I project is the creation of a drug that allows for the specific depletion of a subclass of human antibodies (IgG4) that cause several different human diseases. Current treatments that deplete human antibodies do it without regard to antibody subclass, leading to a broadly suppressed immune system. In addition, there are over 10…
Is this right?
We copy this from the public NSF award record. Your award notice and NSF always win. If a date looks wrong, check Research.gov.